<div id="readability-page-1"><article>Integrated BioPharma, Inc. ((OTCQX:INBP)) (the &#34;Company&#34; or &#34;INBP&#34;) reports its financial results for the quarter ended March 31, 2026.Revenue for the quarter ended March 31, 2026 was $10.1 million compared to $13.9 million for the quarter ended March 31, 2025, a decrease of $3.8 million or 27.3%. The Company had an operating loss of $1.1 million in the quarter ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million.Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended March 31, 2026 of approximately $1.8 million and operating income of approximately $1.4 million for the nine-month period ended March 31, 2025.For the quarters ended March 31, 2026 and 2025, the Company had a net loss of $0.8 million and net income of approximately $0.6 million, respectively. The Company's net (loss) income per share of common stock and diluted net (loss) income per share of common stock for the quarters ended March 31, 2026 and 2025 were $(0.03) and $0.02 per share of common stock, respectively.For the nine-month periods ended March 31, 2026 and 2025, the Company had a net loss of $1.5 million and net income of approximately $1.0 million, respectively. The Company's net (loss) income per share of common stock and diluted net (loss) income per share of common stock for the nine months ended March 31, 2026 and 2025 were $(0.05) and $0.03 per share of common stock, respectively.&#34;Our revenue decreased by approximately 15% in the nine-month period ended March 31, 2026 from the nine-month period ended March 31, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 90% and 83% of total revenue in the nine months ended March 31, 2026 and 2025, respectively,&#34; stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay.A summary of our financial results for the three months and nine months ended March 31, 2026 and 2025 follows:INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts) (Unaudited)<table><tbody><tr><td rowspan="1"></td><td></td><td colspan="6">Three Months Ended</td><td></td><td></td><td colspan="6">Nine Months Ended</td><td></td></tr><tr><td></td><td></td><td colspan="6">March 31,</td><td></td><td></td><td colspan="6">March 31,</td><td></td></tr><tr><td></td><td></td><td colspan="2">2026</td><td></td><td></td><td colspan="2">2025</td><td></td><td></td><td colspan="2">2026</td><td></td><td></td><td colspan="2">2025</td><td></td></tr><tr><td></td><td></td><td colspan="2"></td><td></td><td></td><td colspan="2"></td><td></td><td></td><td colspan="2"></td><td></td><td></td><td colspan="2"></td><td></td></tr><tr><td>Total revenue</td><td></td><td>$</td><td colspan="1">10,107</td><td></td><td></td><td>$</td><td colspan="1">13,947</td><td></td><td></td><td>$</td><td colspan="1">34,076</td><td></td><td></td><td>$</td><td colspan="1">40,178</td><td></td></tr><tr><td>Cost of sales</td><td></td><td></td><td colspan="1">10,383</td><td></td><td></td><td></td><td colspan="1">12,396</td><td></td><td></td><td></td><td colspan="1">33,304</td><td></td><td></td><td></td><td colspan="1">36,085</td><td></td></tr><tr><td>Gross profit</td><td></td><td></td><td colspan="1">(276</td><td>)</td><td></td><td></td><td colspan="1">1,551</td><td></td><td></td><td></td><td colspan="1">772</td><td></td><td></td><td></td><td colspan="1">4,093</td><td></td></tr><tr><td>Selling and administrative expenses</td><td></td><td></td><td colspan="1">809</td><td></td><td></td><td></td><td colspan="1">812</td><td></td><td></td><td></td><td colspan="1">2,608</td><td></td><td></td><td></td><td colspan="1">2,662</td><td></td></tr><tr><td>Operating (loss) income</td><td></td><td></td><td colspan="1">(1,085</td><td>)</td><td></td><td></td><td colspan="1">739</td><td></td><td></td><td></td><td colspan="1">(1,836</td><td>)</td><td></td><td></td><td colspan="1">1,431</td><td></td></tr><tr><td>Other income, net</td><td></td><td></td><td colspan="1">50</td><td></td><td></td><td></td><td colspan="1">39</td><td></td><td></td><td></td><td colspan="1">123</td><td></td><td></td><td></td><td colspan="1">36</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td></tr><tr><td>(Loss) income before income taxes</td><td></td><td></td><td colspan="1">(1,035</td><td>)</td><td></td><td></td><td colspan="1">778</td><td></td><td></td><td></td><td colspan="1">(1,713</td><td>)</td><td></td><td></td><td colspan="1">1,467</td><td></td></tr><tr><td>Income tax (benefit) expense, net</td><td></td><td></td><td colspan="1">(198</td><td>)</td><td></td><td></td><td colspan="1">167</td><td></td><td></td><td></td><td colspan="1">(237</td><td>)</td><td></td><td></td><td colspan="1">481</td><td></td></tr><tr><td>Net (loss) income</td><td></td><td>$</td><td colspan="1">(837</td><td>)</td><td></td><td>$</td><td colspan="1">611</td><td></td><td></td><td>$</td><td colspan="1">(1,476</td><td>)</td><td></td><td>$</td><td colspan="1">986</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td></tr><tr><td>Net (loss) income per share:</td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td></tr><tr><td>Basic</td><td></td><td>$</td><td colspan="1">(0.03</td><td>)</td><td></td><td>$</td><td colspan="1">0.02</td><td></td><td></td><td>$</td><td colspan="1">(0.05</td><td>)</td><td></td><td>$</td><td colspan="1">0.03</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td></tr><tr><td>Diluted</td><td></td><td>$</td><td colspan="1">(0.03</td><td>)</td><td></td><td>$</td><td colspan="1">0.02</td><td></td><td></td><td>$</td><td colspan="1">(0.05</td><td>)</td><td></td><td>$</td><td colspan="1">0.03</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td></tr><tr><td colspan="1">Weighted average common shares outstanding:</td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td></tr><tr><td>Basic</td><td></td><td></td><td colspan="1">31,059,610</td><td></td><td></td><td></td><td colspan="1">30,300,720</td><td></td><td></td><td></td><td colspan="1">31,059,610</td><td></td><td></td><td></td><td colspan="1">30,190,869</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td><td></td><td></td><td colspan="1"></td><td></td></tr><tr><td>Diluted</td><td></td><td></td><td colspan="1">31,059,610</td><td></td><td></td><td></td><td colspan="1">31,514,591</td><td></td><td></td><td></td><td colspan="1">31,059,610</td><td></td><td></td><td></td><td colspan="1">30,960,916</td><td></td></tr></tbody></table>About Integrated BioPharma Inc. (INBP)Integrated BioPharma, Inc. (&#34;INBP&#34;) is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words &#34;expects,&#34; &#34;anticipates,&#34; believes,&#34; intends,&#34; &#34;estimates,&#34; &#34;should,&#34; &#34;would,&#34; &#34;strategy,&#34; &#34;plan&#34; and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled &#34;Risk Factors&#34; in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.Contact: Dina Masi, CFO Integrated BioPharma, Inc. investors@ibiopharma.com 888.319.6962SOURCE: Integrated BioPharma, Inc.View the original press release on ACCESS Newswire<img height="0" src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2NTQxMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="0" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2NTQxMw"/></article></div>

520690

516930

LABU

Integrated BioPharma, Inc. (OTCQX:INBP) reported a revenue decline of 27.3% for Q1 2026, totaling $10.1 million, compared to $13.9 million in Q1 2025. The company experienced an operating loss of $1.1 million in Q1 2026, contrasting with an operating income of $0.7 million in Q1 2025. For the nine-month period ending March 31, 2026, revenue was $34.1 million, down 15.2% from $40.2 million in the same period last year, with a net loss of $1.5 million. The company attributes the revenue drop to reliance on a few major customers.

StockTitan

Bosera Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Direxion S&P Biotech Bull 3X

iShares US Medical Devices

VanEck Biotech ETF

Bosera Hang Seng Health Care ETF(QDII)

iShares Biotechnology ETF

E Fund CSI Biotechnology Theme ETF

iShares US Pharma

Health Care Select Sector SPDR

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

iShares Global Healthcare

VG Health

Invesco Nasdaq Biotechnology ETF

iShares US Healthcare Providers

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

GF CSI HK Innovative Drugs Industry ETF(QDII)

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Invesco Biotechnology & Genome ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Tianhong CNI BIOMEDICINE ETF

SPDR S&P Health

First Trust NYSE Arca Biotech Index Fd

China Merchants CSI Biotechnology Theme ETF

SPDR S&P Health Equip

ChinaAMC CSI All Share Health Care Devices ETF

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026 | INBP Stock News